STOCK TITAN
  1. Home
  2. Sec-filings
  3. RMD
  4. [Form 4] RESMED INC Insider Trading Activity

RMD insider Form 4: GC holds 9,841 shares after tax withholdings

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ResMed Inc. (RMD) reported an insider transaction by Michael J. Rider, Global General Counsel, on 11/11/2025. The filing shows issuer share withholdings for taxes upon RSU vesting (transaction code F).

Withholdings were 135.075, 173.725, 715.489, and 500.735 shares of common stock at $250.1 per share, tied to RSU grants dated 11/18/2021, 11/16/2022, 11/16/2023, and 11/20/2024. After these transactions, Rider beneficially owned 9,841 shares directly. Holdings include 38.9396 shares acquired on 10/31/2025 through the ResMed Employee Stock Purchase Plan.

Positive

  • None.

Negative

  • None.
Insider Rider Michael J
Role Global General Counsel
Type Security Shares Price Value
Tax Withholding ResMed Common Stock 135.075 $250.10 $34K
Tax Withholding ResMed Common Stock 173.725 $250.10 $43K
Tax Withholding ResMed Common Stock 715.489 $250.10 $179K
Tax Withholding ResMed Common Stock 500.735 $250.10 $125K
Holdings After Transaction: ResMed Common Stock — 11,231 shares (Direct)
Footnotes (1)
  1. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. Includes 38.9396 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rider Michael J
(Last) (First) (Middle)
9001 SPECTRUM CENTER BLVD
(Street)
SAN DIEGO CA 92123
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Global General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
ResMed Common Stock 11/11/2025 F(1) 135.075 D $250.1 11,231(2) D
ResMed Common Stock 11/11/2025 F(3) 173.725 D $250.1 11,057 D
ResMed Common Stock 11/11/2025 F(4) 715.489 D $250.1 10,342 D
ResMed Common Stock 11/11/2025 F(5) 500.735 D $250.1 9,841 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021.
2. Includes 38.9396 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan.
3. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022.
4. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023.
5. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024.
Michael J. Rider, Global General Counsel and Secretary 11/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ResMed (RMD) disclose in this Form 4?

An insider transaction by Global General Counsel Michael J. Rider on 11/11/2025 involving share withholdings for RSU tax obligations (code F).

Who is the reporting person in RMD’s Form 4?

Michael J. Rider, Global General Counsel and Secretary of ResMed Inc.

What transactions were reported and at what price?

Issuer withholdings of 135.075, 173.725, 715.489, and 500.735 shares at $250.1 per share to cover RSU taxes.

Which RSU grants vested to trigger the tax withholdings?

RSUs granted on 11/18/2021, 11/16/2022, 11/16/2023, and 11/20/2024.

How many shares does the insider own after the transactions?

Following the reported transactions, the insider beneficially owned 9,841 shares directly.

Does the holding include shares from an employee purchase plan?

Yes. It includes 38.9396 shares purchased on 10/31/2025 through the ResMed Employee Stock Purchase Plan.